Trevi Therapeutics to Detail Haduvio Progress at Oppenheimer Conference

Event summary

  • Trevi Therapeutics CEO Jennifer Good and CFO David Hastings will participate in a fireside chat at the Oppenheimer Healthcare Life Sciences Conference on February 25, 2026.
  • The conference is virtual and will be held February 25-26, 2026.
  • Haduvio™ (oral nalbuphine ER) is Trevi's investigational therapy targeting chronic cough in IPF, non-IPF ILD, and RCC.
  • The company estimates ~150,000 U.S. patients with IPF and ~228,000 with non-IPF ILD experience uncontrolled chronic cough.

The big picture

Trevi Therapeutics is targeting a significant unmet need in chronic cough management, a condition affecting hundreds of thousands of patients with IPF, ILD, and RCC. The lack of FDA-approved therapies creates a substantial market opportunity, but the company faces challenges in demonstrating efficacy and navigating regulatory hurdles. The conference participation signals an effort to bolster investor confidence and communicate progress on Haduvio's development.

What we're watching

Clinical Data
The fireside chat will likely focus on Haduvio’s clinical trial results; investor sentiment will hinge on the perceived robustness and potential for regulatory approval.
Market Adoption
Given the large patient populations with IPF, non-IPF ILD, and RCC, the success of Haduvio will depend on the company's ability to effectively reach and treat these patients, and to differentiate from existing, albeit inadequate, therapies.
Regulatory Pathway
While nalbuphine isn’t currently scheduled by the DEA, any future changes in opioid regulation could significantly impact Haduvio’s development and commercialization timeline.

Related topics

Drug Development